Upcoming IPO: Fourfront files DRHP at BSE to launch SME IPO. Details here
The company has submitted its Draft Red Herring Prospectus (DRHP) to BSE SME as part of its upcoming IPO. The company plans to issue 65,00,000 new equity shares, each with a face value of ₹ 10.
The IPO proceeds will be used for part-financing the Proposed Project FF, meeting additional working capital needs, investing in its wholly owned subsidiary for the Proposed Project EV, funding the subsidiary's working capital requirements, and for general corporate purposes. These funds will help the company achieve its strategic goals and enhance its market position.
Beeline Capital Advisors Private Limited has been appointed as the Book Running Lead Manager, while MUFG Intime India Private Limited will act as the Registrar to the Issue.
Fourfront Limited is a manufacturing company specializing in electromechanical and power electronics products for the automotive industry.
Operating under its flagship brand, the company produces switches, USB chargers, DC-DC converters, onboard chargers, Power Distribution Units, and other electronic components catering to both conventional and electric vehicles.
With a strong presence in the commercial vehicle segment, Fourfront serves multiple leading OEMs and industrial product manufacturers across India. The company operates from a 30,000 sq. ft. integrated facility in Chinchwad, Maharashtra, equipped with advanced engineering software, semi-automatic assembly lines, SMT technology, and a full-fledged in-house testing lab.
For the period ending March 31, 2024, the company posted revenue of ₹ 12,865.84 lakhs, with an EBITDA of ₹ 3,219.76 lakhs and a profit after tax (PAT) of ₹ 2,099.29 lakhs. In comparison, for the period ending December 31, 2024, it reported revenue of ₹ 7,081.06 lakhs, EBITDA of ₹ 1,595.98 lakhs, and PAT of ₹ 952.39 lakhs.
Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
30 minutes ago
- Business Standard
Lupin launches nasal spray in US, part of 200-drug pipeline by FY30
Indian pharmaceutical major Lupin on Thursday announced the launch of a new nasal spray — Ipratropium Bromide Nasal Solution — in the United States market. The product is available in two strengths: 0.03 per cent and 0.06 per cent. The company stated that the spray is used to treat runny nose (rhinorrhoea) caused by allergies, the common cold or other non-allergic conditions. It is suitable for both adults and children, depending on the prescribed strength. The product is the generic version of a nasal spray called Atrovent, which is already available in the US market. The spray is considered bioequivalent, meaning it acts in the same way in the body as the reference drug. Lupin has a strong presence in the US and European pharmaceutical markets. As reported by Business Standard in May, the company is targeting a greater share of revenue from its complex generics portfolio in the US and Europe. With a pipeline of over 200 products over the next five years, Lupin expects the revenue share from complex generics to reach 62 per cent by FY30. The contribution from such products is projected at 21 per cent by FY26. Complex generics include high-value products such as inhalers, injectables, transdermal patches and ophthalmic solutions, which typically contain more sophisticated active ingredients and delivery mechanisms. Generic drugs are copies of branded medicines that have gone off-patent. Complex generics differ from simple generics in terms of formulation, technology and margin potential. On Friday, Lupin's shares closed at ₹1,978 on the Bombay Stock Exchange, up ₹22.40 or 1.15 per cent.
Business Standard
2 hours ago
- Business Standard
Fourfront Limited Files DRHP On BSE SME For IPO
PNN Mumbai (Maharashtra) [India], July 4: Fourfront Limited (Fourfront, the Company), an automotive component manufacturer with design capabilities for electromechanical and power electronics products for the EV and industrial automotive sectors, has announced plans to enter the primary market with an IPO. The company has filed its Draft Red Herring Prospectus with BSE SME in preparation for the IPO. The company plans to issue 65,00,000 fresh equity shares with a face value of ₹ 10 each. As the company advances with its IPO plans, Part-financing the Proposed Project FF, Funding incremental working capital requirements, Investment in our wholly owned Subsidiary for financing the Proposed Project EV, funding its incremental working capital requirement and general corporate purposes. The capital raised will support the company's strategic objectives, strengthen its competitive. Beeline Capital Advisors Private Limited has been appointed as the Book Running Lead Manager to the Issue, while MUFG Intime India Private Limited will serve as the Registrar to the Issue. About Fourfront Limited: Fourfront Limited is a manufacturing company specializing in electromechanical and power electronics products for the automotive industry. Operating under its flagship brand, the company produces switches, USB chargers, DC-DC converters, onboard chargers, Power Distribution Units, and other electronic components catering to both conventional and electric vehicles. With a strong presence in the commercial vehicle segment, Fourfront serves multiple leading OEMs and industrial product manufacturers across India. (ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same)
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Chemkart India IPO opens on July 7: Check price band, GMP, key dates, more
Chemkart India IPO: The initial public offering (IPO) of food and health ingredients distributor Chemkart India will open for subscription on Monday, July 7, 2025. The Mumbai-based company aims to raise ₹80.08 crore through a fresh issue of 2.6 million equity shares and an offer for sale (OFS) of 0.62 million shares. The company has reserved around 50 per cent of the issue for qualified institutional buyers (QIBs), 35 per cent for retail investors and 15 per cent for non-institutional investors (NIIs). Here are the key details of Chemkart India IPO: Chemkart India IPO price band, lot size Chemkart India has set the price band for its IPO in the range of ₹236 to ₹248 per equity share. The minimum lot size for an application is 600 shares. A retail investor would require a minimum investment amount of ₹2,97,000 to bid for at least two lots at the upper end price. The minimum investment required for high net-worth individuals (HNIs) is ₹4,46,400 for three lots. Chemkart India IPO key dates According to the RHP, the three-day subscription window will tentatively close on Wednesday, July 7, 2025. The basis of the allotment of shares is likely to be finalised on or before Thursday, July 10, 2025. Shares of Chemkart India will be listed on the BSE SME platform, tentatively on Monday, July 14, 2025. Chemkart India IPO registrar, lead manager Bigshare Services is the registrar of the issue. Smart Horizon Capital Advisors is the sole book-running lead manager. Chemkart India IPO objective According to the red herring prospectus (RHP), the company plans to use the net fresh issue proceeds for setting up a manufacturing facility through investment in the wholly-owned subsidiary, Easy Raw Materials, and repayment of certain borrowings. The remaining funds will be used for general corporate purposes. Chemkart India IPO GMP The unlisted shares of Chemkart India were trading flat at ₹248, the upper price band as of 3 PM on Friday, according to sources tracking unofficial market activities. About Chemkart India Incorporated in 2020, Mumbai-based Chemkart India provides nutritional, health and sports supplement products. It offers products across mainly seven product categories, including Amino Acids, Health Supplement, Herbal Extract, Nucleotide, Protein, Sports Nutrition, and Vitamin.
